Direxion Daily Semiconductor Bear 3X Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $40.69, while Vertex Pharmaceuticals Incorporated trades at $525.98 (market cap $134.25B). Which is the better fit depends on your goals.
| SOXS | VRTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $1.49K | $529.65 |
52-Week Low | $32.50 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Signals from Pluang's Aura AI — not financial advice
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $39.56, down 12.5% in the past 24 hours amid a bearish technical signal. The stock split 1:10 on July 15, 2026, and paid a $0.04 dividend in June 2026. Technical indicators show oversold conditions with an RSI of 26.30, while moving averages signal a downtrend.
The outlook remains highly speculative due to SOXS's inverse leverage structure, which amplifies losses in rising markets. Risks include semiconductor sector volatility and the ETF's decay from daily rebalancing. It suits only aggressive traders betting against chip stocks, not long-term investors.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Trailing returns across standard periods
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →